Advertisement

Acta Endoscopica

, Volume 10, Issue 4, pp 307–316 | Cite as

Jéjuno-iléite ulcéreuse à la Clofazimine Aspects radiologiques et endoscopiques

  • P. Mainguet
  • A. Bourlond
  • A. Saussez de Temmerman
  • J. Pringot
  • J. Haot
Article

Résumé

Les auteurs rapportent deux observations d’entérite ulcéreuse à la Clofazimine caractérisée par des lésions érosives à prédominance iléale.

La Clofazimine — dérivé du tartrate de phendimetrazine — utilisée dans le traitement de la lèpre, du pyoderma gangrenosum et du lupus erythémateux chronique, provoque des lésions œdémateuses et ulcéreuses aphtoïdes du grêle, lentement régressives après arrêt du médicament.

Le diagnostic des lésions reste radiologique, mais l’entéroscopie dans un cas a permis leur mise en évidence au niveau jéjunal. L’histologie n’est pas spécifique. Des lésions d’entérite à eosinophiles et des dépôts de cristaux de Clofazimine dans les ganglions mésentériques et la paroi intestinale ont été mis en évidence lors d’autopsies de sujets décédés de la lèpre.

Mots-clés

Clofazimine entéroscopie intestin grêle jéjuno-iléite ulcéreuse 

Ulcerative jejuno-ileitis related to Clofazimine endoscopic and radiological features

Summary

The authors report two cases of ulcerative enteritis related to clofazimine characterised by erosive lesions predominantly in the ileum.

Clofazimine, a derivative of phendimetrazine tartrate used in the treatment of leprosy, pyoderma gangrenosum and chronic lupus erythematosus, causes oedematous, ulcerative, aphtoid lesions of the small intestine which slowly regress once the medication is stopped.

The diagnosis of the lesions is primarily radiological, although, in one case, enteroscopy was able to reveal such lesions in the jejunum. The histology is nonspecific. Autopsies of subjects who died from leprosy revealed eosinophilic enteritis lesions and Clofazimine crystal deposits in the mesenteric lymph nodes and in the walls of the intestine.

Key-words

Clofazimine enteroscopy jejuno-ileitis small intestine ulcer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. 1.
    ATKINSON A.J., SHEAGREN J.N., RUBIO J.B., KNIGHT V. — Evaluation of B 663 in human leprosy.Int. J. Lep., 1967,35, 119–127.Google Scholar
  2. 2.
    BALAKRISHNAN S., DESIKAN K.V. and RAMU G. — Quantitative estimation of Clofazimine in tissues.Leprosy in India, 1976,48, 732–738.PubMedGoogle Scholar
  3. 3.
    BARRY V.C., BELTON J.G., CONALTY M.L., DENOONY J.M., EDWARD D.W., O’SULLIVAN J.F., TWONEY D., WINDER F. — A few series of phenazine (rimino-compounds) with high antituberculosis activity.Nature (Lond.), 1957,179, 1013–1015.CrossRefGoogle Scholar
  4. 4.
    BARRY V.C., CONALTY M.L. — Antituberculosis activity in the phenazine series II.N3-substituted anilino-aposafranines (rimino-compounds) and some derivatives.Am. Rev. Tuberc. Pulm. Dis., 1958,78, 62–73.Google Scholar
  5. 5.
    BEUREY J., WEBER M., DELROUS J.L., CHAULIEU Y. — Pyoderma gangrenosum: thérapeutique par Clofazimine.Ann. Derm. Venereol., 1977,104, 631–634.PubMedGoogle Scholar
  6. 6.
    BRANDT L. — Phagocytosis-promoting effect of Clofazimine (B 663) in patients with subnormal granulocyte function.Scan. J. Haemat., 1971,8, 400–404.Google Scholar
  7. 7.
    BRANDT L., GARTNER I., NILSSON P.G., OLOFSSON T. — Pyoderma gangrenosum associated with regional enteritis.Acta Med. Scand., 1977,201, 141–144.PubMedGoogle Scholar
  8. 8.
    BROWNE S.G., HOGERZEIL L.M. — B 663 in the treatment of leprosy. Preliminary report of a pilot trial.Lepr. Rev., 1962,33, 6–10.PubMedGoogle Scholar
  9. 9.
    CLAUDY A.L., GOGUE Y., VOLLE H. — Pyoderma gangrenosum associé à une polyarthrite séro-négative.Ann. Derm. Venereol., 1978,105, 701–704.PubMedGoogle Scholar
  10. 10.
    CONALTY M.L., JACKSON R.D. — Uptake by reticulo-endothelial cells of the rimino-phenazine B 663 (2 P-Chloroanilino-5 P-Chlorophenyl-3: 5-dihydro-3 isopropylinino-phenazine).Brit. J. Exp. Path., 1962,6, 650–654.Google Scholar
  11. 11.
    CONALTY M.L., BARRY V.S., JINA A. — The antileprosy agent B 663 (Clofazimine) and the reticulo-endotheliel system.International Journal of Leprosy, 1971,39, 479–492.Google Scholar
  12. 12.
    DE BERGEYCK E., JANSSENS P.G., DE MUYNDK A. — Ileitis granulomatosa: radiologische diagnose na langdurige toediening van Clofazimine.Ned. T. Geneesk., 1979, 123–146.Google Scholar
  13. 13.
    DESIKAN K.V., RAMANUJAM K., RAMU G., BALAKRISHNAN S. — Autopsy findings in a case of lepromatous leprosy treated by Clofazimine.Lep. Rev., 1975,46, 181–189.Google Scholar
  14. 14.
    DESIKAN K.V., BALAKRISHNAN S. — Tissue levels of Clofazimine in a case of leprosy.Lepr., Rev., 1976,47, 107–113.Google Scholar
  15. 15.
    DUPRE A., BONAFE J.L., LASSERE J., ALBRAREL N., CHRISTOL B. — Traitement du lupus érythémateux chronique par le lamprène (Clofazimine). Etude préliminaire.Ann. Dermatol. Vénéréol., 1978,105, 423–425.PubMedGoogle Scholar
  16. 16.
    HASTINGS R.C., JACOBSON R.R., TRAUTMAN J.R. — Long-terne Clinical Toxicity studies with Clofazimine (B 663) in leprosy.Internat. J. of Leprosy, 1976,44, 287–293.Google Scholar
  17. 17.
    KRIVANEK J., PAVER W.K., KOSSARD S., CAINS G. — Clofazimine (lamprène) in the treatment of discoid lupus erythematosus.Aust. J. Derm., 1976,17, 108–110.CrossRefGoogle Scholar
  18. 18.
    JOPLING W.H. — Complications of treatment with Clofazimine (lamprène B 663).Lepr. Rev., 1976,47, 1.PubMedGoogle Scholar
  19. 19.
    MACKEY J.P., BARNES J. — Clofazimine in the treatment of discoid lupus erythematous.Brit. J. Dermat., 1974,91, 93–96.CrossRefGoogle Scholar
  20. 20.
    MASON G.H., ELLIS-PEGLER R.B., ARTHUR J.F. — Clofazimine and eosinophilic enteritis.Lepr. Rev., 1977,48, 175–180.PubMedGoogle Scholar
  21. 21.
    MICHAELSSON G., MOLIN L., OHMAN S., LINDSTROM B., SKOGH M., TROLIN I. — Clofazimine: a new agent for the treatment of pyoderma gangrenosum.Arch. Dermatol., 1976,112, 344–349.PubMedCrossRefGoogle Scholar
  22. 22.
    RAMU G., IYER C.G.S. — Side effects of Clofazimine therapy.Leprosy in India, 1976,48, 722–731.PubMedGoogle Scholar
  23. 23.
    ROSTANT M. — Le lamprene en léprologie.Act. Leprol., 1972,46–47, 93–103.Google Scholar
  24. 24.
    SABET T., NEWLIN C., FRIEDMAN H. — Effects of RES blokade on antibody formation. I. Suppressed cellular and humoral haemolysin responses in mice injected with carbon particles.Immunology, 1969,16, 433.PubMedGoogle Scholar
  25. 25.
    SHEAGREN J.N. — Antimalarial effect of B 663 in mice infected with plasmodium berghei.J. of. Parasitology, 1968,54, 1250.CrossRefGoogle Scholar
  26. 26.
    YAWALKAR S.J., VISCHER W. — Lamprene (Clofamizine) in leprosy.Lepr. Rev., 1979,30, 135–144.Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • P. Mainguet
    • 1
  • A. Bourlond
    • 1
  • A. Saussez de Temmerman
    • 1
  • J. Pringot
    • 1
  • J. Haot
    • 1
  1. 1.Cliniques Universitaires St-Luc U.C.L.BruxellesBelgique

Personalised recommendations